This unique mechanism allows CTLA‐4 to act as an effector molecule by depleting co‐stimulatory ligands extracellularly, thereby increasing activation threshold and dampening responses to weak antigens, including tumour antigens and autoantigens. The gene discussed is CTLA4; the disease is neoplasm.